Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Ocular Therapeutix Q3 2026 Results: Net Loss of $94.8M, Loss Widens

Ocular Therapeutix reported a decrease in cash and cash equivalents to $530.6 million as of September 30, 2026, compared to $737.1 million at year-end 2025. Total assets decreased to $605.6 million, while total liabilities increased slightly to $164.7 million. The company is currently focused on Phase 3 clinical trials for AXPAXLI in wet AMD and NPDR.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue12.914.5
Net income-94.8-69.4
EPS (diluted, $ a share)$-0.42$-0.38

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-11.5%
Source

10-Q filed with the SEC, NASDAQ: OCUL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Ocular Therapeutix, Inc: key numbers

Share price
$6.01Close, Nov 16
Market cap
$1.32B
Shares outstanding
220.02MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Ocular Therapeutix, Inc

All →
4:29 PM ET Form 4
Insider Selling

Ocular Therapeutix Chief Business Officer Namrata Saroj Sells $232K of Stock

Namrata Saroj, Chief Business Officer, sold 35,370 shares of Ocular Therapeutix, Inc at $6.55 a share, worth $232K in total on Nov 5, 2026. Shares held after the trade: 220,522 (-13.8%).

Value
$232K
Shares
35,370
Price
$6.55
Role
Chief Business Officer
Holding change
-13.8%
Trade date
Nov 5, 2026
7:28 AM ET 8-K
Leadership Change

Ocular Therapeutix Leadership Change

Ocular Therapeutix appointed Riad Sherif, M.D., to its Board of Directors as a Class I member, effective November 6, 2026. Dr. Sherif, currently the CEO of Oculis Holding AG and a former Alcon executive, received an initial equity grant of 88,000 stock options and 28,000 restricted stock units as part of his appointment.

Counterparty
Riad Sherif, M.D.
7:09 AM ET 8-K
Financial Results

Ocular Therapeutix Financial Results

Ocular Therapeutix reported Q3 2026 financial results, highlighting a cash position of $530.6 million and an expected runway into 2028. The company remains on track to submit its NDA for AXPAXLI in wet AMD during Q4 2026 following a positive pre-NDA meeting with the FDA in September.

Term
Q3 2026

“2026 has been a transformational year for Ocular Therapeutix and we are in a strong position as we prepare to submit our NDA for AXPAXLI in wet AMD under the 505(b)(2) regulatory pathway. Frequent injections define today’s wet AMD treatment experience, and we believe AXPAXLI has the transformative potential to drastically reduce the burden on patients and caregivers.”

Pravin U. Dugel, MD, Executive Chairman, President and CEO of Ocular Therapeutix
4:15 PM ET 8-K
Leadership Change

Ocular Therapeutix Leadership Change

Sanjay Nayak, M.B.B.S., Ph.D., notified Ocular Therapeutix of his resignation as Chief Strategy Officer, effective October 16, 2026. Dr. Nayak is leaving the company to become the Chief Executive Officer of a privately-held company.

5:01 PM ET Form 4
Insider Selling

Ocular Therapeutix CLO Todd Anderman Sells $87.4K of Stock

Todd Anderman, CLO, sold 11,984 shares of Ocular Therapeutix, Inc at $7.29 a share, worth $87.4K in total on Oct 8, 2026. Shares held after the trade: 140,484 (-7.9%).

Value
$87.4K
Shares
11,984
Price
$7.29
Role
CLO
Holding change
-7.9%
Trade date
Oct 8, 2026
4:44 PM ET Form 4
Insider Selling

Ocular Therapeutix Chief Development Officer Peter Kaiser Sells $70.4K of Stock

Peter Kaiser, Chief Development Officer, sold 9,990 shares of Ocular Therapeutix, Inc at $7.05 a share, worth $70.4K in total on Oct 2, 2026. Shares held after the trade: 254,388 (-3.8%).

Value
$70.4K
Shares
9,990
Price
$7.05
Role
Chief Development Officer
Holding change
-3.8%
Trade date
Oct 2, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.